Navigation Links
Chemotherapy before radiotherapy for testicular cancer could reduce long-term side-effects
Date:8/16/2013

Giving men with testicular cancer a single dose of chemotherapy alongside radiotherapy could improve the effectiveness of treatment and reduce the risk of long-term side-effects, a new study reports. As many as 96% of men with testicular cancer now survive at least ten years from diagnosis (1), but more advanced forms need to be treated with combination chemotherapy which can have serious long-term complications. Researchers at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have therefore been searching for new treatments that would reduce the risk of relapse after initial treatment and so spare as many men as possible from needing combination chemotherapy.

The new pilot study, published in the August issue of prestigious journal the Annals of Oncology, tested a new treatment in a pilot study of men with stage IIA and IIB testicular seminoma where the cancer has spread to the lymph nodes in the abdomen.

The researchers showed that giving chemotherapy drug carboplatin before radiotherapy could reduce relapse rates compared with radiotherapy alone cutting the numbers of men who would need follow-up treatment. It also allowed radiation doses to be reduced. The study was funded by The Institute of Cancer Research (ICR), the Bob Champion Cancer Trust and Cancer Research UK, as well as through the NIHR Biomedical Research Centre at The Royal Marsden and the ICR.

Researchers gave 51 men with stage IIA and IIB testicular seminoma a single cycle of carboplatin a low toxicity form of chemotherapy followed three to four weeks later by radiotherapy. Most of the men were aged below 50, over a range of 18-73 years.

Adding carboplatin to patients' treatment plans allowed doctors to give a lower dose of radiation over a smaller area of the body for most of the men in the study. Some 39 of the men in the study had their prescription of radiation reduced from the standard 35 Grays (Gy) of radiat
'/>"/>

Contact: Henry French
henry.french@icr.ac.uk
020-715-35312
Institute of Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Neuroblastoma: Autophagy protects from chemotherapy
2. An article in Cell reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer
3. Discovery may help prevent chemotherapy-induced anemia
4. Changes to DNA on-off switches affect cells ability to repair breaks, respond to chemotherapy
5. New way to kill lymphoma without chemotherapy
6. Neutrons help explain why antibiotics prescribed for chemotherapy cause kidney failure
7. Scientists uncover strategy able to dramatically reduce chemotherapys side effects
8. New biomarker for common lung cancer predicts responses to chemotherapy
9. Nanobubbles plus chemotherapy equals single-cell cancer targeting
10. Harmless human virus may be able to boost the effects of chemotherapy
11. Hot flashes before menopause? It can happen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2014)... 6, 2014 - Insilico Medicine, Inc, a Baltimore-based ... age related diseases announced a research collaboration with ... Champions Oncology, Inc (OTC: CSBR). , "There are ... medicine, but Champions Oncology,s TumorGraft technology is unique ... chemotherapy regimen experimentally generating vast amounts of valuable ...
(Date:11/4/2014)... Nov. 5, 2014 – University of Utah engineers developed ... help jet fuel produce electricity without needing to ignite ... to power portable electronics, off-grid power and sensors. , ... in the American Chemical Society journal ACS Catalysis ... a chemical reaction between a fuel and an oxygen-rich ...
(Date:11/4/2014)... study examining only marketing directed at children on ... has found that the majority of black, middle-income ... marketing tactics. , Authored by Arizona State University ... is the first to examine the use of ... fast food restaurants and its relationship to demographics. ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2Jet-fueled electricity at room temperature 2Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3
... alarming invasion of round goby into Great Lakes tributaries: ... A team of scientists from the University of Toronto, ... of Guelph has identified a drastic invasion of round ... of the Thames, Sydenham, Ausable and Grand Rivers. A ...
... awarded through federal stimulus research funding, a Kansas State ... eventually help diabetics preserve their eyesight. Dolores Takemoto, ... from the National Eye Institute to study how a ... protein kinase C gamma, called PKC gamma, and how ...
... , , , WALL, N.J., Aug. ... will be holding its second quarter conference call, which will be broadcast ... Eastern Time. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20050509/BIOKEYLOGO ) , ... International, Inc. Second Quarter 2009 Conference Call, When: ...
Cached Biology News:BIO-key(R) Announces Second Quarter Conference Call Schedule 2
(Date:11/26/2014)... 2014 Deep Research Report on ... in-depth research report on the Ammonium Bifluoride market, ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... China, Japan etc. regions) industry analysis covering macroeconomic ...
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 ... environments. Human exploration of space requires astronauts to maintain ... safety and success, and prevent potential errors and accidents. ... little is known about how cognition is affected by ... affected. Now, Penn Medicine researchers are poised ...
(Date:11/26/2014)... PMG Research, Inc. announced today ... a network of sites that provide clinical research services to ... patient lives through its partnerships with large physician practices and ... site locations in the Southeastern United States and spans over ... board will be held by: Dr. Robert Holmes, ...
(Date:11/26/2014)... TX (PRWEB) November 25, 2014 Continuing ... skincare products, earned three prestigious MarCom Awards for outstanding ... Nerium received a Platinum MarCom Award, the organization’s top ... Event in St. Louis held in April of this ... more than 14,000 attendees. Additionally, Nerium was awarded a ...
Breaking Biology Technology:Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Aug. 22 DNA2.0,Inc. (http://www.DNA20.com ), ... and,Operon Biotechnologies (http://www.operon.com ), a leader ... a partnership to utilize their,synergistic technologies and ... production platform with DNA2.0,s,gene synthesis process, the ...
... 21 ,Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... (SAR) of a class of,internally-developed compounds that ... the company as potential treatments for irritable ... is currently,under evaluation in a Phase 1b ...
... Under Fire, WORCESTER, Mass., Aug. 21 ... proud to announced that Dr.,Robert Lanza, the company,s ... recognized for his research and contributions to stem,cell ... PharmaVOICE (cover,story July/August issue). Dr. Lanza is one ...
Cached Biology Technology:Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 2Advanced Cell Technology's Dr. Robert Lanza Makes List of '100 Most Inspiring People in the Life-Sciences Industry' 3
Human GATA-2 Affinity Purified Polyclonal Ab...
... microPET 120 utilizies CTI Molecular Imaging's proprietary ... same imaging volume as the R4. ... sensitivity of any commerically avaiable PET scanner. ... spatial resolution of any scinitallor based PETsystems. ...
... EVO series offers versatile liquid handling platforms ... a wide variety of life science applications.The ... base sizes (75, 100, 150 and 200 ... a platform that will advance with their ...
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
Biology Products: